Skip to content

Anticoagulation in Emergency General Surgery

Anticoagulation in Emergency General Surgery: Who Bleeds More? The ACES Trial

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04216394
Enrollment
4
Registered
2020-01-02
Start date
2019-10-31
Completion date
2020-11-13
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergency General Surgery

Brief summary

While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outcomes in the EGS population taking DOACs. We hypothesize that patients taking a DOAC will have a higher bleeding incidence and need for an unplanned intervention secondary to hemorrhage in EGS patients undergoing an urgent or emergent operation when compared to patients taking warfarin and antiplatelets.

Detailed description

Emergency general surgery (EGS) represents illnesses of diverse pathology with urgent/emergent treatment needs being the common denominator.A characteristic feature of EGS is its limitation in patient preparation. It is difficult and often impossible to eliminate certain patient dependent factors to reduce the operative risk. It has been reported that the annual case rate in the EGS population is (1,290 per 100,000) higher than the sum of all cancer diagnoses. The EGS burden is substantial and continues to increase. The elderly patient population represents 48% of the overall EGS population. With the increase in the prevalence of atherosclerotic disease in the elderly there has been an increase in the use of antiplatelets and anticoagulants.

Interventions

multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.

Sponsors

Methodist Health System
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* All patients who are confirmed to be taking dabigatran, rivaroxaban, apixaban, warfarin and antiplatelet therapy (aspirin, clopidogril, ticagrelor) undergoing an urgent or emergent surgical intervention by the emergency general surgery service within 24 hours of arrival to the hospital * 18 years of age or over

Exclusion criteria

* Prisoners * Pregnant patients * Those who received an index operation at an outside facility and were transferred * Under 18 years of age

Design outcomes

Primary

MeasureTime frameDescription
Rate of operativeOct 2019 - Aug 2021To determine the bleeding risk and need for unplanned intervention
Number of Participants with interventional radiologyOct 2019 - Aug 2021To determine the bleeding risk and need for unplanned intervention
Number of Participants with ultrasound aspirationOct 2019 - Aug 2021To determine the bleeding risk and need for unplanned intervention

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichael Truitt, MD

Methodist Dallas Medical Center Trauma

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026